2. Search Result
Search Result
Results for "

Smad1

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Natural
Products

3

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12274
    ML347
    Maximum Cited Publications
    7 Publications Verification

    LDN 193719

    		 TGF-β Receptor Cancer
    ML347 (LDN193719) is a highly selective ALK1/ALK2 inhibitor. ML347 has IC50 values of 46 and 32 nM against ALK1 and ALK2, respectively, >300-fold selective over ALK3. ML347 block the phosphorylation of Smad1/5 by TGF-β1 [1] .
    ML347
  • HY-164145
    CDD-1653

    		TGF-β Receptor Others Cancer
    CDD-1653 is a potent and selective BMPR2 inhibitor (IC50=2.8 nM). CDD-1653 reduces the ability of ATP to bind to the kinase domain of BMPR2, thereby affecting the phosphorylation of SMAD1/5/8 transcription factors, which play a key role in the BMP signaling pathway. CDD-1653 can be used to study diseases related to the BMP signaling pathway [1].
    CDD-1653
  • HY-P99359
    Elezanumab

    ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)

    		 TGF-beta/Smad Metabolic Disease
    Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism [1] .
    Elezanumab
  • HY-108527
    CD1530
    1 Publications Verification

    		 RAR/RXR Bacterial TGF-beta/Smad β-catenin MMP Reactive Oxygen Species Infection Metabolic Disease Endocrinology
    CD1530 is an orally active, selective RARγ agonist and antibacterial agent. CD1530 reduces Smad1/5/8 phosphorylation and overall Smad levels. CD1530 reduces β-catenin, MMP9 protein, and ROS levels. CD1530 exhibits activities such as inhibiting heterotopic ossification, promoting Achilles tendon healing, and inhibiting muscle fatty infiltration. CD1530 can be used in the research of orthopedic diseases (such as heterotopic ossification, Achilles tendon injury), muscle diseases (such as muscle fatty infiltration-related diseases) [1] .
    CD1530
  • HY-P99353
    Ascrinvacumab
    2 Publications Verification

    Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962

    		 Anaplastic lymphoma kinase (ALK) Cancer
    Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) [1].
    Ascrinvacumab
  • HY-123900
    AZ12799734

    		TGF-β Receptor Cardiovascular Disease
    AZ12799734 is a selective, orally active TGFBR1 kinase inhibitor with an IC50 of 47 nM. AZ12799734 is also a pan BMP and TGFβ inhibitor [1].
    AZ12799734
  • HY-124697
    BMP signaling agonist sb4
    5 Publications Verification

    		 TGF-β Receptor Cancer
    BMP signaling agonist sb4 is a potent benzoxazole bone morphogenetic protein 4 (BMP4) signaling agonist with a EC50 value of 74 nM, activates BMP signaling by stabilizing intracellular p-SMAD-1/5/9. BMP signaling agonist sb4 activates BMP4 target genes (inhibitors of DNA binding, Id1 and Id3) canonical BMP signaling [1].
    BMP signaling agonist sb4
  • HY-RS13392
    SMAD1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SMAD1 Human Pre-designed siRNA Set A contains three designed siRNAs for SMAD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SMAD1 Human Pre-designed siRNA Set A
    SMAD1 Human Pre-designed siRNA Set A
  • HY-N0946
    (-)-Pinoresinol 4-O-glucoside

    (-)-Pinoresinol 4-O-β-D-glucopyranoside

    		 Glycosidase Metabolic Disease
    (-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease [1] .
    (-)-Pinoresinol 4-O-glucoside
  • HY-173149
    CDD-2789

    		Anaplastic lymphoma kinase (ALK) TGF-beta/Smad TGF-β Receptor Cancer
    CDD-2789 is a highly selective small-molecule inhibitor targeting Activin receptor type 1 (ALK2, also known as ACVR1). It blocks the SMAD1/5 signaling pathway mediated by ALK2/ALK1, thereby effectively suppressing downstream phosphorylation events induced by BMP and activin A. In the NanoBRET cellular model, CDD-2789 exhibits an inhibitory IC50 of 0.54 µM against ALK2. CDD-2789 holds promise for research on ALK2-related diseases, including diffuse intrinsic pontine glioma (DIPG), ependymoma, endometrial cancer, melanoma, non–small cell lung cancer, colorectal cancer, and pancreatic cancer [1].
    CDD-2789

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: